Phase 2 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 55 years old (male or female)
- You have a specific type of genetic change (called a "truncating mutation") in a gene called BAG3
- You have a weakened, enlarged heart (called dilated cardiomyopathy) where your heart is pumping at less than 45% of its normal capacity
- You have moderate heart failure symptoms that affect your daily activities or cause symptoms only during physical activity (known as NYHA Class II or III)
- A blood test shows a certain heart stress marker (NT-proBNP) is above a specific level — the exact level depends on your heart rhythm (confirm with trial site)
- You are willing and able to give your consent and follow the study requirements
Who may not be able to join:
- You have previously had a heart attack, received a heart transplant, or currently use or need a mechanical heart pump (called an LVAD)
- You have received intravenous (IV) medications to support your heart or remove fluid within the last 30 days before joining the trial
- A blood test shows that your body has already developed antibodies that would block the study treatment (called ATC-0187)
- You have any other health condition that the trial doctor believes could put you at unnecessary risk or affect the study results (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: (617) 430-7817
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.